TransMedics Group, Inc.TT

TransMedics Group, Inc.

75.45USDR
−3.97−5.00%
At close at 00:59 GMT
USD
No trades
See on Supercharts

TMDX fundamentals

Key facts

Market capitalization‪2.53 B‬USD
Founded1998
CEOWaleed H. Hassanein
About

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Ownership
‪‪33.56 M‬‬
Free Float shares
‪‪32.42 M‬‬ (96.59%)
Closely held shares
‪‪1.15 M‬‬ (3.41%)
Free Float shares
‪‪32.42 M‬‬ (96.59%)
Closely held shares
‪‪1.15 M‬‬ (3.41%)
Capital structure
Market cap
‪‪2.53 B‬‬
Debt
‪‪518.15 M‬‬
Cash & equivalents
‪‪330.09 M‬‬
Enterprise value
‪‪2.72 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪2.53 B‬‬
Price to earning ratio (P/E)
85.09x
Price to sales ratio (P/S)
7.07x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
85.09x
Price to sales ratio (P/S)
7.07x
Valuation ratios
‪0.00‬
‪4.00‬
‪8.00‬
‪12.00‬
‪16.00‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪1.10 K‬‬
‪‪2.20 K‬‬
‪‪3.30 K‬‬
‪‪4.40 K‬‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−39%‬
‪−26%‬
‪−13%‬
‪0%‬
‪13%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−40.00 M‬‬
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
‪‪120.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
‪‪120.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Liver Organ Care System
Heart Organ Care System
Lung Organ Care System
By country
Period: 2023
United States
All Other Countries

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
‪‪120.00 M‬‬
Actual
Estimate
Earnings
Next:Feb 27, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.12‬
‪0.00‬
‪0.12‬
‪0.24‬
‪0.36‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

TMDX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−200.00 M‬‬
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪150.00 M‬‬
‪‪300.00 M‬‬
‪‪450.00 M‬‬
‪‪600.00 M‬‬
Assets
Liabilities